4.5 Article

Nrf2- and ATF4-Dependent Upregulation of xCT Modulates the Sensitivity of T24 Bladder Carcinoma Cells to Proteasome Inhibition

期刊

MOLECULAR AND CELLULAR BIOLOGY
卷 34, 期 18, 页码 3421-3434

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.00221-14

关键词

-

资金

  1. MEXT/JSPS KAKENHI [20117010, 25293064]
  2. Hirosaki University Institutional Research Grant
  3. Uehara Memorial Foundation
  4. Karoji Memorial Fund for Medical Research of Hirosaki University, Hirosaki University School of Medicine
  5. Hirosaki University
  6. Grants-in-Aid for Scientific Research [20117010, 24500967, 25293064] Funding Source: KAKEN

向作者/读者索取更多资源

The ubiquitin-proteasome pathway degrades ubiquitinated proteins to remove damaged or misfolded protein and thus plays an important role in the maintenance of many important cellular processes. Because the pathway is also crucial for tumor cell growth and survival, proteasome inhibition by specific inhibitors exhibits potent antitumor effects in many cancer cells. xCT, a subunit of the cystine antiporter system x(c)(-), plays an important role in cellular cysteine and glutathione homeostasis. Several recent reports have revealed that xCT is involved in cancer cell survival; however, it was unknown whether xCT affects the cytotoxic effects of proteasome inhibitors. In this study, we found that two stress-inducible transcription factors, Nrf2 and ATF4, were upregulated by proteasome inhibition and cooperatively enhance human xCT gene expression upon proteasome inhibition. In addition, we demonstrated that the knockdown of xCT by small interfering RNA (siRNA) or pharmacological inhibition of xCT by sulfasalazine (SASP) or (S)-4-carboxyphenylglycine (CPG) significantly increased the sensitivity of T24 cells to proteasome inhibition. These results suggest that the simultaneous inhibition of both the proteasome and xCT could have therapeutic benefits in the treatment of bladder tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据